Given the impact of anti-HER2 therapy on reducing SUVmax in lesions, we further explored the relationship between SUVmax and HER2 status (determined by IHC and FISH) in 27 patients imaged before anti-tumor therapy. This evidence concerns the gene ERBB2 and neoplasm.